Viking Therapeutics (VKTX) Convertible Debt (2014 - 2018)

Viking Therapeutics has disclosed Convertible Debt across 5 years of filings, most recently posting $1.5 million for Q1 2018.

• Convertible Debt for Q1 2018 came in at $1.5 million, down 59.6% year-over-year; the trailing twelve-month figure through Mar 2018 was $1.5 million (down 59.6% YoY), and the FY2017 annual result was $1.5 million, changed 0.0% from the prior year.
• Convertible Debt came in at $1.5 million for Q1 2018 at Viking Therapeutics, roughly flat from $1.5 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $3.7 million in Q1 2017 to a low of $1.3 million in Q4 2014.
• The 5-year median for Convertible Debt is $1.5 million (2016), against an average of $1.8 million.
• Across the five-year window, Convertible Debt soared 119.57% in 2016 and tumbled 59.6% in 2018, its largest moves.
• Viking Therapeutics' Convertible Debt stood at $1.3 million in 2014, then surged by 70.2% to $2.2 million in 2015, then slumped by 30.28% to $1.5 million in 2016, then changed by 0.0% to $1.5 million in 2017, then changed by 0.0% to $1.5 million in 2018.
• The last three Convertible Debt figures came in at $1.5 million (Q1 2018), $1.5 million (Q4 2017), and $1.5 million (Q3 2017), per Business Quant data.